Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Munchener Ruckversicherungs-Gesellschaft Aktiengesellschaft Unsponsored ADR (MUVB) AI Stock Analysis

DE:MUVB

Munchener Ruckversicherungs-Gesellschaft Aktiengesellschaft Unsponsored ADR

(Frankfurt:MUVB)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Strong capital and solvencyA 304% solvency ratio and conservative leverage provide substantial protection against underwriting shocks. This supports capacity to retain attractive risks, absorb volatility, and maintain dividends or buybacks through the planning period.
Negative Factors
P&C reinsurance growth pressureThe guidance reduction and lower P&C Re revenue indicate that softer market conditions and disciplined underwriting are limiting top-line expansion. Persistent volume pressure could constrain operating leverage and reduce the contribution from Munich Re's largest business.

Munchener Ruckversicherungs-Gesellschaft Aktiengesellschaft Unsponsored ADR (MUVB) vs. iShares MSCI Germany ETF (EWG)

-20%-15%-10%-5%0%5%10%15%DE:MUVB+6.95%EWG+6.61%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 16.59B
Dividend Yield
4.30%
Average Volume (3M)
781
Price to Earnings (P/E)
10.6
Beta (1Y)
0.50
Revenue Growth
0.06%
EPS Growth
38.82%
Country
Germany
Employees
43,982
Sector
Financial
Sector Strength
68
Industry
Insurance - Reinsurance

Munchener Ruckversicherungs-Gesellschaft Aktiengesellschaft Unsponsored ADR Business Overview & Revenue Model

Company Description

Münchener Rückversicherungs-Gesellschaft AG, commonly known as Munich Re, operates as a global leader in the insurance and reinsurance industries. Its extensive operations are segmented into five primary divisions: Life and Health Reinsurance, Proper...

Munchener Ruckversicherungs-Gesellschaft Aktiengesellschaft Unsponsored ADR Earnings Call Summary

Earnings Call Date:Aug 06, 2026(Q2-2026)|% Change Since:7.92%|Next Earnings Date:Nov 11, 2026
Earnings Call SentimentPositive

The call presented a strong set of operating and financial metrics (robust net income, 23% ROE, solid investment returns, Life Re and ERGO momentum, and a very strong solvency position) that underline the company’s resilience and diversified earnings profile. However, notable challenges remain in P&C reinsurance: top-line softening (EUR 2bn guidance cut), July renewals showing volume (-9%) and price (-5.5%) pressure, and a rising normalized combined ratio (~82% and expected to trend up) partly driven by a large structured transaction. Management emphasizes disciplined underwriting, capital strength, and the ability to redeploy capacity, and remains confident on full-year earnings targets despite near-term top-line and mix headwinds.

Positive Updates

Strong first-half profitability
Net result of EUR 3.9 billion in H1 2026 (already >60% of full-year net income guidance) and a strong Q2 net profit of EUR 2.2 billion, demonstrating robust near-term earnings delivery.

Negative Updates

Normalized combined ratio trend in P&C Re
Normalized combined ratio increased to around 82% in Q2 (headline Q2 combined ratio 68.9% benefiting from low major losses); management expects the normalized 82% to trend upwards through the remainder of the year.

Company Guidance

Munich Re updated its outlook while keeping Ambition 2030 intact: H1 net result was EUR 3.9bn (over 60% of full‑year guidance) and Q2 net profit EUR 2.2bn, with ROE at 23% (vs Ambition target >18%) and Solvency II ~304%; reinsurance revenue guidance was cut by EUR 2bn to EUR 38bn (P&C Re H1 revenue down ~EUR 1.4bn, ~1/3 FX/NDIC), July renewals saw volumes -9% with prices -5.5% and a ~1ppt negative mix, P&C Re Q2 reported combined ratio 68.9% (normalized ~82% and expected to trend up) with reserve releases of ~6pp, and the large structured deal is earning through into 2027; Life & Health Re posted a Q2 total technical result of EUR 528m and H1 >EUR 1bn with CSM stock EUR 16bn; GSI has grown ~EUR 800m p.a. through 2024 with Q2 combined ratio 88.9% (H1 86.3%) and organic growth toward the 5–9% Ambition range; ERGO Q2 net result EUR 321m (Germany EUR 235m, International EUR 86m) and insurance revenue guidance remains EUR 24bn; investment ROI was 5.5% in Q2 (4.2% for H1), running yield 4.0% and reinvestment yield 4.3%; management reiterates targets of ROE >18% and >8% average annual EPS growth and remains committed to dividends and buybacks.

Munchener Ruckversicherungs-Gesellschaft Aktiengesellschaft Unsponsored ADR Peers Comparison

Overall Rating

UnderperformOutperform
Sector (68)

Financial Indicators

DE:MUVB against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ACGLACGL83Outperform$36.29B8.8318.35%―-5.29%14.08%
AXSAXS78Outperform$7.52B7.1317.80%1.65%10.16%7.89%
RGARGA78Outperform$17.29B11.6211.29%1.41%19.54%97.85%
RNRRNR76Outperform$13.71B9.9913.52%0.46%-21.18%-3.27%
Sector *68Neutral$18.00B11.429.92%3.81%9.73%1.22%
EGEG65Neutral$15.76B8.8912.52%1.92%-8.72%250.85%

* Financial Sector Average

Performance Comparison

0%20%40%DE:MUVBACGLAXSEGRGARNRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:MUVB and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:MUVBMunchener Ruckversicherungs-Gesellschaft Aktiengesellschaft Unsponsored ADR10.900.807.97%
ACGLArch Capital109.3121.8424.97%
AXSAxis Capital Holdings106.6012.2512.98%
EGEverest Group, Ltd.417.72107.5734.68%
RGAReinsurance Group Of America267.4183.9945.79%
RNRRenaissancere350.9489.7934.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.